Armand Cognetta

Armand is a highly accomplished scientist with a strong academic background in chemical biology. He holds a PhD from Scripps Research Institute, where he developed chemo-proteomic platforms for drug discovery and co-authored over 20 publications in top-tier journals like Cell, Nature, and Science. His research also led to foundational intellectual property for successful biotech acquisitions. arman+4

As a serial biotech entrepreneur, Armand founded General Proximity, a company focused on pioneering next-generation induced-proximity medicines. He successfully navigated Y Combinator as a solo founder, secured substantial seed funding, and established strategic collaborations with major pharmaceutical companies and leading investors, all aiming to redefine treatment for 'undruggable' diseases. arman+4

Armand has experience in the early stages of biotech startups, having been an early employee at Inzen Therapeutics (now Sonata), where he built their proteomics drug discovery engine. This hands-on experience in platform development informs his current work at General Proximity. arman+2

Beyond his scientific and entrepreneurial pursuits, Armand maintains a broad range of personal interests. He is a passionate advocate for mental health in academia, an avid reader and writer, and engages in demanding physical activities like triathlons and ultra-marathons. These diverse interests reflect a holistic approach to well-being and personal growth. arman+6